Table 1.
Summary of published manuscripts reporting subchronic (≥ 3 consecutive days) pharmacological treatment effects on intravenous (+)-methamphetamine self-administration under a concurrent-choice schedule.
| # | (Dose in mg/kg/injection) | Alternative reinforcer | Species | Main treatment examined | Effect | Ref. |
|---|---|---|---|---|---|---|
| Monoamine transporter substrate treatments | ||||||
| 1 | METH (0.01–0.32) | Food pellet | Rhesus | Effect of D-amphetamine | ─/↓ | 46 |
| Monoamine transporter inhibitor treatments | ||||||
| 2 | METH (0.01–0.32) | Food pellet | Rhesus monkey | Effect of bupropion | ─ | 68 |
| 3 | METH (0.01–0.32) | Food pellet | Rhesus | Effect of methylphenidate and cocaine | ─ | 46 |
| Dopamine receptor antagonist and partial agonist treatments | ||||||
| 4 | METH (0.01–0.3) | Food pellet | Rhesus | Effect of buspirone and PG619 | ─ | 101 |
| 5 | METH (0.01–0.3) | Food pellet | Rhesus | Effect of PG01037 | ─ | 93 |
| 6 | METH (0.01–0.32) | Food pellet | Rhesus | Effect of risperidone | ↑ | 68 |
| Serotonin receptor antagonist treatments | ||||||
| 7 | METH (0.01–0.32) | Food pellet | Rhesus | Effect of pimavanserin | ─ | 113 |
Note: Columns show methamphetamine (METH) doses, the alternative reinforcer, the species in which studies were conducted, the primary treatment examined and outcome, and the reference. Studies are categorized as classes of treatment compounds discussed in the manuscript. A horizontal dashed line (─) represents a pharmacological treatment that did not significantly alter methamphetamine choice up to doses that produced other behavioral effects, such as suppression of rates of operant behavior. A downward arrow (↓) represents a pharmacological treatment that decreased methamphetamine choice. An upward arrow (↑) represents a pharmacological treatment that increased methamphetamine choice.